Request Demo
Last update 14 May 2025
Zibotentan/Dapagliflozin
Last update 14 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists, inhibitors |
Mechanism ETA antagonists(Endothelin receptor type A antagonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS Registry186497-07-4 |
View All Structures (2)
Related
3
Clinical Trials associated with Zibotentan/DapagliflozinNCT06942910
A Multicentre, Randomised, Double-blind, Active-Controlled, 2-arm Parallel-group Treatment, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
NCT06269484
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With Cirrhosis
NCT04991571
A Phase 1, Open-label Study With Two Independent Parts: Collecting Samples for Metabolites in Safety Testing Analysis of Zibotentan After Repeated Administration (Part 1); and a Randomised, Cross-over, Three Period, Three-treatment, Single Dose Study to Assess the Relative Bioavailability of Different Formulations of Zibotentan and Dapagliflozin (Part 2) in Healthy Adult Participants
100 Clinical Results associated with Zibotentan/Dapagliflozin
Login to view more data
100 Translational Medicine associated with Zibotentan/Dapagliflozin
Login to view more data
100 Patents (Medical) associated with Zibotentan/Dapagliflozin
Login to view more data
100 Deals associated with Zibotentan/Dapagliflozin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Kidney Diseases | Phase 3 | United States | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | China | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Japan | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Argentina | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Australia | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Austria | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Brazil | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Bulgaria | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Canada | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | Denmark | 07 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free